Stem Cell Services. Driving Innovation for Stem Cell Researchers

Similar documents
Axol Bioscience SNAPSHOT PRESENTATION ELRIG ADVANCES IN CELL BASED SCREENING Zoe Allen, PhD Product Specialist

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

10:10-10:22. YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32

Stem Cel s Key Words:

The NYSCF Research Institute

Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017

hpsc Growth Medium DXF Dr. Lorna Whyte

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)

Induced Pluripotent Stem Cell

for SCI: Challenges for Entry and Execution of Phase 1 Clinical Trials Challenges and Opportunities of Cellular Therapeutic Development

ANAT 2341 Embryology Lecture 18 Stem Cells

Stem Cells in Life and Disease: Immortality Inside You

Células madre con pluripotencia inducida: posibles aplicaciones clínicas

Overview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014

Stem Cell Principle -

Molecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics

The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017

Matrices sourcebook. Your guide to Gibco extracellular matrices products

PRIME-XV Cell Therapy Products by

Stem Cells: Introduction and Prospects in Regenerative Medicine.

PRIME-XV Cell Therapy Products by

ANAT 3231 Cell Biology Lecture 21 Stem Cells

Matrices Sourcebook Life Technologies extracellular matrices products

Stem Cells, Regenerative Medicine and cgmp (GTP)

Polaris and Callisto: Advances in Cellular Biology. Jordan Moore Senior Field Applications Specialist

NIA Aging Cell Repository

DB3230 Midterm 1 11/15/2013 Name:

Fundamental properties of Stem Cells

Course Agenda. Day One

INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE

BME 177. Engineering stem cells. Gayatri Pal Lecturer Biomolecular Engineering

Stem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan

A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA

Contents. The Right Surface for Every Cell Extracellular Matrices and Biologically Coated Surfaces ECM Mimetic and Advanced Surfaces...

A gateway to academic excellence for Biotech and Pharma

Stem Cells and Cell Culture Developments Within ThermoFisher Scientific

Regenerative Medicine and the Changing Regulatory Landscape

Synthetic Viruses Targeting Cancer

Concept of Integrated Research Platforms

Cellular and Gene Therapy Products - CBER Update

Human induced Pluripotent Stem Cell (ipsc) Line: GM23225*B

Supplementary Data. Supplementary Methods Three-step protocol for spontaneous differentiation of mouse induced pluripotent stem (embryonic stem) cells

Global Leader in Viral Vector Technologies

The Power to Cure: Therapeutic Innovation in Academia

Xeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications

Genetic Basis of Development & Biotechnologies

Stem Cell Research 101

significant concerns no or very low predictive power

Pluripotent Stem Cells From Research to Therapy

Induced Stem Cells in Research and Therapy of Neuropsychiatric Disorders

RXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals

Therapeutic Cell Replacement. Steven McLoon Department of Neuroscience University of Minnesota

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research.

NPTEL Biotechnology Tissue Engineering. Stem cells

WHAT IS EMBRYONIC STEM CELLS

Specialty Lab Services. Deep science at scale

Relative cost of hepatocytes

Regulation of advanced blood cell therapies

Introduction to Assay Development

What IMI means for POLAND

ILLUMINA SEQUENCING SYSTEMS

Supplemental Information. 1. Patent Search Methodology

Stem Cells and Regenerative Medicine: The Future is Now

Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation

Recent years have witnessed an expansion in the disciplines encompassing drug

The flow diagram below shows part of a process to produce a protein, using genetically modified plants.

Human embryonic stem cells for in-vitro developmental toxicity testing

Stem cells and motor neurone disease

CONTRACT ASSAY SERVICES CONTRACT ASSAY SERVICES FOR STEM AND PROGENITOR CELLS

Personalized Healthcare Diagnostik und Therapie aus einer Hand

International summer school on model systems and IPSCs

Triggering Calcium Responses in Various Human ipsc-derived Neural Cell Types. Giorgia Salvagiotto, PhD June 2016

Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium

Break the 3D barrier CORNING 3D CELL CULTURE

Understanding brain diseases from stem cells to clinical trials

Versatility and performance of Lipofectamine Stem Transfection Reagent

ABOUT GLYCOSTEM. Company Overview

TITLE: Induced Pluripotent Stem Cells as Potential Therapeutic Agents in NF1

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014

King George's Medical University UP., Lucknow center for advance research

Supplementary Figure 1.

Webinar July 9, Noon. The Essentials of Diagnostics: Introduction to Molecular Diagnostics

Sabrina Jedlicka. Interactions of Neurons and Materials

Monitoring the Safety of Stem Cell Based Therapeutics in Clinical Trials. Jane Lebkowski Ph.D. ASGCT May 18, 2010

Education Critical to Stem Cell Therapy Pipeline

Peri.4U. Human ipsc-derived peripheral neurons

Stem cell transfection guide

First xeno-free serum replacement for pluripotent stem cells

Mayo Clinic Arizona/Rochester and U. Minnesota

Professor Martin Pera. University of Melbourne Melbourne

Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre

Stem cells in Development

Stem cells in Development

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

Reduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases

ADVANCED MEDIA TECHNOLOGY

Regenerative Medicine and Stem Cell Therapies

QPS Neuropharmacology Overview

Ips Cells Can Be Efficiently Differentiated Back To Mscs Using A Short Exposure To Tgfβ

Transcription:

Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge, MA 02142 617-981-4208 support@cellariabio.com cellariabio.com/stemcell

Cellaria offers the most advanced and comprehensive stem cell services available today. Our single-source service offerings include RNA-mediated ips cell line generation, maintenance, and differentiation to enable the development of next-generation disease models. These disease models are used for pathway biology, drug development, and assessment of molecular and pharmacological mechanisms of action with long-term potential application in the development of the next generation of personalized therapies.

Why RNA? RNA has proven to be the most efficient and clinically relevant reprogramming platform for the generation of human ips cell lines from human skin fibroblasts and peripheral and cord blood endothelial progenitor cells. The combination of this platform and our expertise ensures the delivery of high quality ips cell lines to meet your specific needs.

Our Technical Edge We have assembled a team of stem cell experts who have been working with ips cells from the moment the groundbreaking technology emerged in 2006. We provide single-source solutions for your ipsc needs: primary patient cell culture establishment, RNA reprogramming, ipsc line expansion/banking, characterization, and differentiation. RNA reprogramming service offerings Integration-free, non-viral, safe and efficient Differentiation service offerings Readily available lineages coupled with flexible, efficient and iterative custom solutions Consultative science Industry leading scientific experts will help to develop a costeffective and milestone-driven project to meet your needs Concierge customer and technical support Start-to-finish assistance and support throughout the entire process Cellaria delivers the most comprehensive, milestone-driven and customizable service solutions available. Coupled with concierge technical support by industryleading experts, we enable the next generation of disease models.

Reprogramming Services Primary Patient Sample Cell Line Establishment (3-4 weeks) RNA Reprogramming (2-6 weeks ) Primary Patient Sample Cell Line Establishment (3-4 weeks) Cellaria will work with you to identify and select the proper patient sample source to fit your specific research program needs. Fibroblasts from skin punch or EPCs from blood Human Pathogen Panel and mycoplasma testing 3-4 vials (1M cells per vial) RNA Reprogramming (2-6 weeks) Our team utilizes novel RNA reprogramming technologies that allow for the generation of clinically-compliant and integration-free human ipscs from human fibroblasts and endothelial progenitor cells in as little as two weeks. Use of non-integrating RNA technology ensures that your ips cell lines have never been exposed in vitro to retained viral programs or DNA vectors that may result in genomic integration/alteration. Expansion and Banking of Primary Patient Cells (3-4 weeks) Cellaria s expansion and banking protocols incorporate xeno- and feederfree cell culture substrates, culture, and cryopreservation media, to ensure consistent, high viability cell cultures upon thaw. Derived ips cell lines can be expanded and banked to meet alternate customer specifications.

Expansion and Banking of Primary Patient Cells (3-4 weeks) Basic Characterization (1-4 weeks) Basic Characterization (1-4 weeks) Cellaria s core services include ICC or FACS to ensure pluripotency expression, mycoplasma/pathogen screening to ensure sterility, and fingerprinting analysis to ensure ipsc identity. Additional services include karyotyping to assess genomic stability, qrt-pcr of pluripotency genes, or tri-lineage differentiation to assess in vitro pluripotential. Advanced Characterization For specialized support, Cellaria goes beyond basic characterization services to include in vivo teratoma formation assay or directed differentiation to terminal cell type. Differentiation Services Cellaria has industry-leading expertise in ips cell modeling that allows for the most flexible, adaptable, and customizable solutions for your differentiated cell type of interest. Our stage-specific targets, combined with consistent scientific communication throughout the project, ensures an efficient and tailored process. Current cell types offered include, but are not limited to: Neural Progenitor Cells (NPCs) Cortical, Dopaminergic, Motor Neurons Hepatocytes Cardiomyocytes 1-2 months 2-3 months 1-2 months 1-2 months

About Cellaria Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patient s biology. All of our models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria s cell models capture novel cell populations from difficult-toculture tumors. For RNA-mediated ips cell line derivation, Cellaria s cell models enable interrogation of disease-specific mechanisms of action. Cellaria s innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure. Start your consultation today. Contact us at 617-981-4208 or visit us at cellariabio.com/stemcell 675 W. Kendall St. Cambridge, MA 02142 617-981-4208 support@cellariabio.com SEPT2017